Artiva Biotherapeutics, Inc. ((ARTV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artiva Biotherapeutics, Inc. is conducting a Phase 1 clinical trial titled A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood-Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and preliminary activity of AB-101, a natural killer cell therapy, in combination with B-cell depleting monoclonal antibodies in patients with relapsed or refractory lupus nephritis or systemic lupus erythematosus.
The intervention being tested includes AB-101, an allogeneic NK cell therapy, used alone or in combination with B-cell depleting monoclonal antibodies such as rituximab or obinutuzumab. These treatments are intended to enhance the immune response in patients who have not responded to standard care.
The study is designed as a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. Participants will receive either AB-101 alone or in combination with monoclonal antibodies, following a regimen of cyclophosphamide and fludarabine.
The study began on February 9, 2024, with the latest update on August 12, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results, which can impact market perceptions.
The update on this study could influence Artiva Biotherapeutics’ stock performance, as positive results might boost investor confidence and interest in the company’s innovative therapies. The competitive landscape in lupus treatment is evolving, and successful outcomes could position Artiva as a leader in this niche market.
The study is ongoing, and further details are available on the ClinicalTrials portal.